CUBAN VACCINES ABDALA AND MAMBISA AGAINST COVID-19

• Published in: International journal of infectious diseases 2023-05, Vol.130, p.S9-S10
• Main Authors: Guillen, G., Limonta, M., Muzio, V., Lemos, G., Hernández-Bernal, F., Chinea, G., Gonzalez-Roche, D., Martin, A., Bequet, M., Marques, G., Zamora, J., Brito, J., Enriquez-Puertas, J., Cruz-Sui, O., Noa, E., Gonzalez-Sosa, N., Dubed, M., Valdibia, I., Palenzuela, A., Valdes, J., Carlos-Pia, N., Rodriguez, M., Ayala, M., Pimentel, E., Martinez, E.
• Format: Article
• Language: English
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2023.04.027

With the first case of COVID-19 in Cuba on March 11, 2020, the Center for Genetic Engineering and Biotechnology in Havana began an extensive vaccine program. Two vaccines based on RBD recombinant protein were developed, one for systemic administration “Abdala” and one mucosal vaccine “Mambisa”. Abdala received the EUA in July 2021 and "Mambisa" completed its clinical development as a booster dose for convalescent subjects. Two doses (25 and 50 µg) and two schedules (0-14-28 and 1-28-56 days) were evaluated in phase I clinical trials with volunteers 19 to 54 years old. The phase II and III clinical trials were also double-blind, randomized, and placebo-controlled, and included respectively 660 and 48,000 volunteers from 19 to 80 years. The anti-RBD titers were evaluated using a quantitative ELISA system developed at the Center for Immunoassay, Havana Cuba, and ELECSYS system from Roche. The RBD to ACE2 plate-based binding competitive ELISA was performed to determine the inhibitory activity of the anti-RBD polyclonal sera on the binding of the hFc-ACE2 coated plates. The neutralization antibody titers were detected by a traditional virus microneutralization assay (MN50). The Abdala vaccine reached 92.28% efficacy. The epidemic was frankly under control in Cuba after the vaccine introduction having reached the highest levels of cases and mortality in July 2021 with the dominance of the Delta strain. The peak of the Omicron wave, unlike other countries, did not reach half of the cases of the Delta wave with a significant reduction in mortality. The mucosal vaccine candidate "Mambisa" completed its clinical development as a booster dose for convalescent subjects reaching the trial end-point. Vaccine composition based on RBD recombinant antigen alone is sufficient to achieve high vaccine efficacy comparable to mRNA and live vaccine platforms. The vaccine also protects against different viral variants including Delta and Omicron strains.